Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics

Pharmacological Reviews

Volumn 65, Issue 4, 2013, Pages 1214-1256

  Jacobson, Orit ^a   Chen, Xiaoyuan ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2' DEOXY 2' FLUORO BETA D ARABINOFURANOSYL)THYMINE F 18; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE C 11; [4 [(3 IODOPHENYL)AMINO] 7 [2 [2 [2 [2 [2 [2 ([FLUORINE 18]FLUOROETHOXY) ETHOXY] ETHOXY] ETHOXY] ETHOXY] ETHOXY] QUINAZOLINE 6 YL ACRYLAMIDE] F 18; ANNEXIN V F 18; ANNEXIN V TC 99M; BEVACIZUMAB ZR 89; CETUXIMAB; CETUXIMAB DOTA CU 64; CETUXIMAB ZR 89; ERLOTINIB C 11; FLUCICLATIDE F 18; GEFITINIB C 11; GEFITINIB F 18; IBRITUMOMAB TIUXETAN; LUMINESPIB F 18; MONOCLONAL ANTIBODY J591; N [[4,7,10 TRIS (CARBOXYMETHYL) 1,4,7,10 TETRAAZACYCLODODEC 1 YL]ACETYL] D PHENYLALANYL L CYSTEINYL 3 (1 NAPHTHALENYL) L ALANYL D TRYPTOPHYL L LYSYL L THREONYL N 2 HYDROXY 1 (HYDROXYMETHYL)PROPYL] GA 68; ONARTUZUMAB; ONARTUZUMAB ZR 89; PALBOCICLIB; PANITUMUMAB; PANITUMUMAB DOTA CU 64; PANITUMUMAB ZR 89; RADIOISOTOPE; S ACETYLMERCAPTOACETYLTRIGLYCINE ANTISENSE OLIGONUCLEOTIDE TC 99M; SMALL INTERFERING RNA TC 99M; TRASTUZUMAB; TRASTUZUMAB CU 64; TRASTUZUMAB ZR 89; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGGRESSIVENESS; BREAST METASTASIS; COLORECTAL CANCER; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MOLECULAR IMAGING; NONHODGKIN LYMPHOMA; NONHUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE;

EID: 84888166688     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.113.007625     Document Type: Review

References (362)

1. Abate C, Ferorelli S, Contino M, Marottoli R, Colabufo NA, Perrone R, and Berardi F (2011) Arylamides hybrids of two high-affinity s2 receptor ligands as tools for the development of PET radiotracers. Eur J Med Chem 46:4733-4741.
2. Abiraj K, Mansi R, Tamma ML, Fani M, Forrer F, Nicolas G, Cescato R, Reubi JC, and Maecke HR (2011) Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. JNucl Med 52:1970-1978.
3. Abourbeh G, Dissoki S, Jacobson O, Litchi A, Ben Daniel R, Laki D, Levitzki A, and Mishani E (2007) Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. Nucl Med Biol 34:55-70.
4. Adams JM (2003) Ways of dying: multiple pathways to apoptosis. Genes Dev 17: 2481-2495.
5. Adams JM and Cory S (2007) Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol 19:488-496.
6. AdamsMC, Turkington TG, Wilson JM, and Wong TZ (2010) A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol 195:310-320.
7. Aerts HJ, Dubois L, Perk L, Vermaelen P, van Dongen GA, Wouters BG, and Lambin P (2009) Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 50:123-131.
8. Allen AM, Ben-Ami M, Reshef A, Steinmetz A, Kundel Y, Inbar E, Djaldetti R, Davidson T, Fenig E, and Ziv I (2012) Assessment of response of brain metastases to radiotherapy by PET imaging of apoptosis with 18F-ML-10. Eur J Nucl Med Mol Imaging 39:1400-1408.
9. Aloya R, Shirvan A, Grimberg H, Reshef A, Levin G, Kidron D, Cohen A, and Ziv I (2006) Molecular imaging of cell death in vivo by a novel small molecule probe. Apoptosis 11:2089-2101.
10. Anastasi A, Erspamer V, and Bucci M (1971) Isolation and structure of bombesin and alytesin, 2 analogous active peptides from the skin of the European amphibians Bombina and Alytes. Experientia 27:166-167.
11. Arteaga CL (2002) Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7 (Suppl 4):31-39.
12. Atfy M, Eissa M, Salah HE, and El Shabrawy DA (2012) Role of urokinase plasminogen activator receptor (CD87) as a prognostic marker in acute myeloid leukemia. Med Oncol 29:2063-2069.
13. auf dem Keller U, Bellac CL, Li Y, Lou Y, Lange PF, Ting R, Harwig C, Kappelhoff R, Dedhar S, and Adam MJ, et al. (2010) Novel matrix metalloproteinase inhibitor [18F]marimastat-aryltrifluoroborate as a probe for in vivo positron emission tomography imaging in cancer. Cancer Res 70:7562-7569.
14. Backer MV and Backer JM (2012) Imaging key biomarkers of tumor angiogenesis. Theranostics 2:502-515.
15. Bader HL and Hsu T (2012) Systemic VHL gene functions and the VHL disease. FEBS Lett 586:1562-1569.
16. Bagatell CJ and Bremner WJ (1996) Androgens in men-uses and abuses. N Engl J Med 334:707-714.
17. Baum RP and Kulkarni HR (2012) THERANOSTICS: From molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy-The Bad Berka experience. Theranostics 2:437-447.
18. Bauvois B (2012) New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 1825:29-36.
19. Bauwens M, De Saint-Hubert M, Devos E, Deckers N, Reutelingsperger C, Mortelmans L, Himmelreich U, Mottaghy FM, and Verbruggen A (2011) Site-specific 68Ga-labeled Annexin A5 as a PET imaging agent for apoptosis. Nucl Med Biol 38:381-392.
20. Beer AJ, Grosu AL, Carlsen J, Kolk A, Sarbia M, Stangier I, Watzlowik P, Wester HJ, Haubner R, and Schwaiger M (2007) [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 13:6610-6616.
21. Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, Weber WA, and Schwaiger M (2005) Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med 46:1333-1341.
22. Beer AJ, Kessler H, Wester HJ, and Schwaiger M (2011) PET imaging of integrin aVb3 expression. Theranostics 1:48-57.
23. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Hammer J, Loidl W, Pirich C, Fogelman I, and Langsteger W (2009) The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol 11:446-454.
24. Bello L, Francolini M, Marthyn P, Zhang J, Carroll RS, Nikas DC, Strasser JF, Villani R, Cheresh DA, and Black PM (2001) a(v)b3 and a(v)b5 integrin expression in glioma periphery. Neurosurgery 49:380-389, discussion 390.
25. Bem WT, Thomas GE, Mamone JY, Homan SM, Levy BK, Johnson FE, and Coscia CJ (1991) Overexpression of sigma receptors in nonneural human tumors. Cancer Res 51:6558-6562.
26. Bhardwaj V, Cascone T, Cortez MA, Amini A, Evans J, Komaki RU, Heymach JV, and Welsh JW (2013) Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy. Cancer 119:1768-1775.
27. Blankenberg F (2002) To scan or not to scan, it is a question of timing: technetium-99m-annexin V radionuclide imaging assessment of treatment efficacy after one course of chemotherapy. Clin Cancer Res 8:2757-2758.
28. Blankenberg FG (2008) In vivo detection of apoptosis. J Nucl Med 49 (Suppl 2): 81S-95S.
29. Blot E, Laberge-Le Couteulx S, Jamali H, Cornic M, Guillemet C, Duval C, Hellot MF, Pille JY, Picquenot JM, and Veyret C (2008) CXCR4 membrane expression in node-negative breast cancer. Breast J 14:268-274.
30. Blumenschein GR Jr, Mills GB, and Gonzalez-Angulo AM (2012) Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol 30:3287-3296.
31. Bögler O and Mikkelsen T (2003) Angiogenesis in glioma: molecular mechanisms and roadblocks to translation. Cancer J 9:205-213.
32. Bonasera TA, Ortu G, Rozen Y, Krais R, Freedman NM, Chisin R, Gazit A, Levitzki A, and Mishani E (2001) Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase. Nucl Med Biol 28:359-374.
33. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, and Zhu J, et al. (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21-28.
34. Brooks PC, Clark RA, and Cheresh DA (1994a) Requirement of vascular integrin a v b 3 for angiogenesis. Science 264:569-571.
35. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, and Cheresh DA (1994b) Integrin avb3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157-1164.
36. Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, Schilling T, Haufe S, Herrmann T, and Haberkorn U (2007) Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 34:1617-1626.
37. Buck AK, Herrmann K, Shen C, Dechow T, Schwaiger M, and Wester HJ (2009) Molecular imaging of proliferation in vivo: positron emission tomography with [18F]fluorothymidine. Methods 48:205-215.
38. Burger JA and Peled A (2009) CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 23:43-52.
39. Cai W, Chen K, He L, Cao Q, Koong A, and Chen X (2007) Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 34:850-858.
40. Cai W, Niu G, and Chen X (2008a) Imaging of integrins as biomarkers for tumor angiogenesis. Curr Pharm Des 14:2943-2973.
41. Cai W, Niu G, and Chen X (2008b) Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imaging 35:186-208.
42. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296:1655-1657.
43. Carpenter CD, Ingraham HA, Cochet C, Walton GM, Lazar CS, Sowadski JM, Rosenfeld MG, and Gill GN (1991) Structural analysis of the transmembrane domain of the epidermal growth factor receptor. J Biol Chem 266:5750-5755.
44. Chang JW, Chou CL, Huang SF, Wang HM, Hsieh JJ, Hsu T, and Cheung YC (2007) Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer. Lung Cancer 58:414-417.
45. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, and Fagone P, et al. (2011) Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2:135-164.
46. Chen K and Chen X (2011) Positron emission tomography imaging of cancer biology: current status and future prospects. Semin Oncol 38:70-86.
47. 1F-FMISO. Nucl Med Commun 33:1096-1102.
48. Chen P, Cameron R, Wang J, Vallis KA, and Reilly RM (2003) Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. J Nucl Med 44:1469-1478.
49. Chen X (2006) Multimodality imaging of tumor integrin alphavbeta3 expression. Mini Rev Med Chem 6:227-234.
50. Chen X, Liu S, Hou Y, Tohme M, Park R, Bading JR, and Conti PS (2004a) MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol 6:350-359.
51. Chen X, Tohme M, Park R, Hou Y, Bading JR, and Conti PS (2004b) Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide. Mol Imaging 3:96-104.
52. Cheng Q, Lu L, Grafström J, Olofsson MH, Thorell JO, Samén E, Johansson K, Ahlzén HS, Stone-Elander S, and Linder S, et al.; Sel-tag Imaging Project (2012) Combining [11C]-AnxA5 PET imaging with serum biomarkers for improved detection in live mice of modest cell death in human solid tumor xenografts. PLoS ONE 7:e42151.
53. Cheng Z, De Jesus OP, Kramer DJ, De A, Webster JM, Gheysens O, Levi J, Namavari M, Wang S, and Park JM, et al. (2010) 64Cu-labeled affibody molecules for imaging of HER2 expressing tumors. Mol Imaging Biol 12:316-324.
54. Cheng Z, De Jesus OP, Namavari M, De A, Levi J, Webster JM, Zhang R, Lee B, Syud FA, and Gambhir SS (2008) Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. J Nucl Med 49:804-813.
55. Chin FT, Shen B, Liu S, Berganos RA, Chang E, Mittra E, Chen X, and Gambhir SS (2012) First experience with clinical-grade ([18F]FPP(RGD2): an automated multistep radiosynthesis for clinical PET studies. Mol Imaging Biol 14:88-95.
56. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, and Green DR (2004) Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303:1010-1014.
57. Choura M and Rebaï A (2011) Receptor tyrosine kinases: from biology to pathology. J Recept Signal Transduct Res 31:387-394.
58. Cohen MH, Williams GA, Sridhara R, Chen G, and Pazdur R (2003) FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 8:303-306.
59. Comis RL (2005) The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer. Oncologist 10:467-470.
60. Comuzzi B, Nemes C, Schmidt S, Jasarevic Z, Lodde M, Pycha A, Bartsch G, Offner F, Culig Z, and Hobisch A (2004) The androgen receptor co-activator CBP is upregulated following androgen withdrawal and is highly expressed in advanced prostate cancer. J Pathol 204:159-166.
61. Corsten MF, Hofstra L, Narula J, and Reutelingsperger CP (2006) Counting heads in the war against cancer: defining the role of annexin A5 imaging in cancer treatment and surveillance. Cancer Res 66:1255-1260.
62. Coussens LM, Fingleton B, and Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295:2387-2392.
63. Dalton JT, Mukherjee A, Zhu Z, Kirkovsky L, and Miller DD (1998) Discovery of nonsteroidal androgens. Biochem Biophys Res Commun 244:1-4.
64. Daughaday WH and Deuel TF (1991) Tumor secretion of growth factors. Endocrinol Metab Clin North Am 20:539-563.
65. Degterev A, Boyce M, and Yuan J (2003) A decade of caspases. Oncogene 22: 8543-8567.
66. Dehdashti F, Laforest R, Gao F, Shoghi KI, Aft RL, Nussenbaum B, Kreisel FH, Bartlett NL, Cashen A, and Wagner-Johnston N, et al. (2013) Assessment of cellular proliferation in tumors by PET using 18F-ISO-1. J Nucl Med 54:350-357.
67. de Jong IJ, Pruim J, Elsinga PH, Jongen MM, Mensink HJ, and Vaalburg W (2002) Visualisation of bladder cancer using (11)C-choline PET: first clinical experience. Eur J Nucl Med Mol Imaging 29:1283-1288.
68. Deng Y and Chang S (2007) Role of telomeres and telomerase in genomic instability, senescence and cancer. Lab Invest 87:1071-1076.
69. De Silva RA, Peyre K, Pullambhatla M, Fox JJ, Pomper MG, and Nimmagadda S (2011) Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465. J Nucl Med 52:986-993.
70. Deri MA, Zeglis BM, Francesconi LC, and Lewis JS (2013) PET imaging with 89Zr: from radiochemistry to the clinic. Nucl Med Biol 40:3-14.
71. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, van Dongen GA, Schröder CP, Lub-de Hooge MN, and de Vries EG (2010) Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 87:586-592.
72. Doss M, Kolb HC, Zhang JJ, Bélanger MJ, Stubbs JB, Stabin MG, Hostetler ED, Alpaugh RK, von Mehren M, and Walsh JC, et al. (2012) Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans. J Nucl Med 53:787-795.
73. Egeblad M and Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174.
74. Eiblmaier M, Meyer LA, Watson MA, Fracasso PM, Pike LJ, and Anderson CJ (2008) Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines. J Nucl Med 49:1472-1479.
75. Elsinga PH (2002) Radiopharmaceutical chemistry for positron emission tomography. Methods 27:208-217.
76. Enslow MS, Zollinger LV, Morton KA, Butterfield RI, Kadrmas DJ, Christian PE, Boucher KM, Heilbrun ME, Jensen RL, and Hoffman JM (2012) Comparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma. Clin Nucl Med 37:854-861.
77. Essmann F and Schulze-Osthoff K (2012) Translational approaches targeting the p53 pathway for anti-cancer therapy. Br J Pharmacol 165:328-344.
78. Fahham D, Weiss ID, Abraham M, Beider K, Hanna W, Shlomai Z, Eizenberg O, Zamir G, Izhar U, and Shapira OM, et al. (2012) In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer. J Thorac Cardiovasc Surg 144:1167-1175.
79. Fan Z, Masui H, Altas I, and Mendelsohn J (1993) Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 53:4322-4328.
80. Fani M, Maecke HR, and Okarvi SM (2012) Radiolabeled peptides: valuable tools for the detection and treatment of cancer. Theranostics 2:481-501.
81. Fantl WJ, Johnson DE, and Williams LT (1993) Signalling by receptor tyrosine kinases. Annu Rev Biochem 62:453-481.
82. Felding-Habermann B (2003) Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis 20:203-213.
83. Felding-Habermann B, Mueller BM, Romerdahl CA, and Cheresh DA (1992) Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. J Clin Invest 89:2018-2022.
84. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, and Yu J, et al. (1995) The RNA component of human telomerase. Science 269:1236-1241.
85. Ferretti G, Felici A, Papaldo P, Fabi A, and Cognetti F (2007) HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol 19:56-62.
86. Fiechter M, Gebhard C, Ghadri JR, Fuchs TA, Pazhenkottil AP, Nkoulou RN, Herzog BA, Altorfer U, Gaemperli O, and Kaufmann PA (2013) Myocardial perfusion imaging with (13)N-Ammonia PET is a strong predictor for outcome. Int J Cardiol 167:1023-1026.
87. Fiechter M, Ghadri JR, Gebhard C, Fuchs TA, Pazhenkottil AP, Nkoulou RN, Herzog BA, Wyss CA, Gaemperli O, and Kaufmann PA (2012) Diagnostic value of 13N-ammonia myocardial perfusion PET: added value of myocardial flow reserve. J Nucl Med 53:1230-1234.
88. Fulda S (2009) Apoptosis pathways and their therapeutic exploitation in pancreatic cancer. J Cell Mol Med 13:1221-1227.
89. Furumoto S, Takashima K, Kubota K, Ido T, Iwata R, and Fukuda H (2003) Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor. Nucl Med Biol 30:119-125.
90. Furusato B, Mohamed A, Uhlén M, and Rhim JS (2010) CXCR4 and cancer. Pathol Int 60:497-505.
91. Gabriel M, Andergassen U, Putzer D, Kroiss A, Waitz D, Von Guggenberg E, Kendler D, and Virgolini IJ (2010) Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients. Q J Nucl Med Mol Imaging 54:92-99.
92. Gaertner FC, Kessler H, Wester HJ, Schwaiger M, and Beer AJ (2012) Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med Mol Imaging 39 (Suppl 1):S126-S138.
93. Gao F, Li L, Liu T, Hao N, Liu H, Tan L, Li H, Huang X, Peng B, and Yan C, et al. (2012) Doxorubicin loaded silica nanorattles actively seek tumors with improved anti-tumor effects. Nanoscale 4:3365-3372.
94. Gartel AL (2009) p21(WAF1/CIP1) and cancer: a shifting paradigm? Biofactors 35: 161-164.
95. Gauchez AS, Du Moulinet D'Hardemare A, Lunardi J, Vuillez JP, and Fagret D (1999) Potential use of radiolabeled antisense oligonucleotides in oncology. Anticancer Res 19 (6B):4989-4997.
96. Gil-da-Costa R, Braun A, and Martin A (2006) Using PET H2O15 brain imaging to study the functional-anatomical correlates of non-human primate communication. Methods 38:221-226.
97. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, and Jain RK (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91:1071-1121.
98. Gofrit ON, Mishani E, Orevi M, Klein M, Freedman N, Pode D, Shapiro A, Katz R, Libson E, and Chisin R (2006) Contribution of 11C-choline positron emission tomography/computerized tomography to preoperative staging of advanced transitional cell carcinoma. J Urol 176:940-944, discussion 944.
99. Goldenberg DM, Chang CH, Rossi EA, J W, McBride, and Sharkey RM (2012) Pretargeted molecular imaging and radioimmunotherapy. Theranostics 2:523-540.
100. Greer SN, Metcalf JL, Wang Y, and Ohh M (2012) The updated biology of hypoxiainducible factor. EMBO J 31:2448-2460.
101. Groot-Wassink T, Aboagye EO, Wang Y, Lemoine NR, Keith WN, and Vassaux G (2004) Noninvasive imaging of the transcriptional activities of human telomerase promoter fragments in mice. Cancer Res 64:4906-4911.
102. Grosu AL, Souvatzoglou M, Röper B, Dobritz M, Wiedenmann N, Jacob V, Wester HJ, Reischl G, Machulla HJ, and Schwaiger M, et al. (2007) Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 69:541-551.
103. Grüner JM, Paamand R, Højgaard L, and Law I (2011) Brain perfusion CT compared with15O-H2O-PET in healthy subjects. EJNMMI Res 1:28-38.
104. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, and Hamers R (1993) Naturally occurring antibodies devoid of light chains. Nature 363:446-448.
105. Hanahan D and Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70.
106. Hanahan D and Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674.
107. 64)Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry. Radiat Oncol 7:89-99.
108. Hara T, Inagaki K, Kosaka N, and Morita T (2000) Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET. J Nucl Med 41: 1507-1513.
109. Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, Becker KF, Goebel M, Hein R, and Wester HJ, et al. (2005) Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med 2:e70.
110. Haug AR, Cindea-Drimus R, Auernhammer CJ, Reincke M, Wängler B, Uebleis C, Schmidt GP, Göke B, Bartenstein P, and Hacker M (2012) The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors. J Nucl Med 53: 1686-1692.
111. Havelund BM, Holdgaard PC, Rafaelsen SR, Mortensen LS, Theil J, Bender D, Pløen J, Spindler KL, and Jakobsen A (2013) Tumour hypoxia imaging with 18F-fluoroazomycinarabinofuranoside PET/CT in patients with locally advanced rectal cancer. Nucl Med Commun 34:155-161.
112. Heinlein CA and Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25:276-308.
113. Heiss WD, Wienhard K, Wagner R, Lanfermann H, Thiel A, Herholz K, and Pietrzyk U (1996) F-Dopa as an amino acid tracer to detect brain tumors. JNucl Med 37:1180-1182.
114. Herbst RS (2003) Erlotinib (Tarceva): an update on the clinical trial program. Semin Oncol 30(3, Suppl 7)34-46.
115. Herbst RS and Kies MS (2003) Gefitinib: current and future status in cancer therapy. Clin Adv Hematol Oncol 1:466-472.
116. Hiyama E and Hiyama K (2003) Telomerase as tumor marker. Cancer Lett 194: 221-233.
117. Ho Jin Cho JDL, Park JY, Yun M, Kang WJ, Walsh JC, Kolb H, and Zhang JJ (2009) First in human evaluation of a newly developed integrin binding PET tracer, 18F-RGD-K5 in patients with breast cancer: Comparison with 18F-FDG uptake pattern and microvessel density. J Nucl Med 50(Suppl. 2):1910.
118. Hofland LJ and Lamberts SW (2003) The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24:28-47.
119. Höglund J, Shirvan A, Antoni G, Gustavsson SA, Långström B, Ringheim A, Sörensen J, Ben-Ami M, and Ziv I (2011) 18F-ML-10, a PET tracer for apoptosis: first human study. J Nucl Med 52:720-725.
120. Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, and Lewis JS (2010) 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 51:1293-1300.
121. Holm NT, Abreo F, Johnson LW, Li BD, and Chu QD (2009) Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC). Breast Cancer Res Treat 113:293-299.
122. Hornick JR, Spitzer D, Goedegebuure P, Mach RH, and Hawkins WG (2012) Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands. Surgery 152(3, Suppl 1)S152-S156.
123. Hu S, Kiesewetter DO, Zhu L, Guo N, Gao H, Liu G, Hida N, Lang L, Niu G, and Chen X (2012) Longitudinal PET imaging of doxorubicin-induced cell death with 18F-Annexin V. Mol Imaging Biol 14:762-770.
124. Hua H, Li M, Luo T, Yin Y, and Jiang Y (2011) Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci 68:3853-3868.
125. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, Xiao T, Schafer J, Lee ML, and Schmittgen TD, et al. (2008) Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE 3:e3694.
126. Hunter T (1984) The epidermal growth factor receptor gene and its product. Nature 311:414-416.
127. Hwang R and Varner J (2004) The role of integrins in tumor angiogenesis. Hematol Oncol Clin North Am 18:991-1006, vii.
128. Hyde R, Taylor PM, and Hundal HS (2003) Amino acid transporters: roles in amino acid sensing and signalling in animal cells. Biochem J 373:1-18.
129. Ichihara E, Kiura K, and Tanimoto M (2011) Targeting angiogenesis in cancer therapy. Acta Med Okayama 65:353-362.
130. Inubushi M, Saga T, Koizumi M, Takagi R, Hasegawa A, Koto M, Wakatuki M, Morikawa T, Yoshikawa K, and Tanimoto K, et al. (2013) Predictive value of 39-deoxy-39-[18F]fluorothymidine positron emission tomography/computed tomography for outcome of carbon ion radiotherapy in patients with head and neck mucosal malignant melanoma. Ann Nucl Med 27:1-10.
131. Ishida Y, Kawai K, Magata Y, Takeda R, Hashiguchi H, Abe H, Mukai T, and Saji H (2004) Changes in dopamine D2 receptors and 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine uptake in the brain of 6-hydroxydopamine-lesioned rats. Neurodegener Dis 1:109-112.
132. Jackowski S (1994) Coordination of membrane phospholipid synthesis with the cell cycle. J Biol Chem 269:3858-3867.
133. Jacobson O and Chen X (2010) PET designated flouride-18 production and chemistry. Curr Top Med Chem 10:1048-1059.
134. Jacobson O, Weiss ID, Kiesewetter DO, Farber JM, and Chen X (2010) PET of tumor CXCR4 expression with 4-18F-T140. J Nucl Med 51:1796-1804.
135. Jacobson O, Weiss ID, Szajek L, Farber JM, and Kiesewetter DO (2009) 64Cu-AMD3100-a novel imaging agent for targeting chemokine receptor CXCR4. Bioorg Med Chem 17:1486-1493.
136. Jacobson O, Weiss ID, Szajek LP, Niu G, Ma Y, Kiesewetter DO, Farber JM, and Chen X (2011) PET imaging of CXCR4 using copper-64 labeled peptide antagonist. Theranostics 1:251-262.
137. Jacobson O, Weiss ID, Szajek LP, Niu G, Ma Y, Kiesewetter DO, Peled A, Eden HS, Farber JM, and Chen X (2012) Improvement of CXCR4 tracer specificity for PET imaging. J Control Release 157:216-223.
138. Jadvar H (2012) Can choline PET tackle the challenge of imaging prostate cancer? Theranostics 2:331-332.
139. Jager PL, de Korte MA, Lub-de Hooge MN, van Waarde A, Koopmans KP, Perik PJ and de Vries EG (2005) Molecular imaging: what can be used today. Cancer Imaging 5 Spec No A:S27-32.
140. Jagoda EM, Lang L, Bhadrasetty V, Histed S, Williams M, Kramer-Marek G, Mena E, Rosenblum L, Marik J, and Tinianow JN, et al. (2012) Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab. J Nucl Med 53:1592-1600.
141. Jhanwar YS and Straus DJ (2006) The role of PET in lymphoma. J Nucl Med 47: 1326-1334.
142. Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, Carano RA, Kasman I, Mai E, and Young J, et al. (2008) MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 68: 4360-4368.
143. Jora C, Mattakarottu JJ, Aniruddha PG, Mudalsha R, Singh DK, Pathak HC, Sharma N, Sarin A, Prince A, and Singh G (2011) Comparative evaluation of 18F-FDOPA, 13N-AMMONIA, 18F-FDG PET/CT and MRI in primary brain tumors-A pilot study. Indian J Nucl Med 26:78-81.
144. Jungbluth AA, Stockert E, Huang HJ, Collins VP, Coplan K, Iversen K, Kolb D, Johns TJ, Scott AM, and Gullick WJ, et al. (2003) A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci USA 100:639-644.
145. Kabolizadeh P, Kubicek GJ, Heron DE, Ferris RL, and Gibson MK (2012) The role of cetuximab in the management of head and neck cancers. Expert Opin Biol Ther 12: 517-528.
146. Kaira K, Oriuchi N, Shimizu K, Ishikita T, Higuchi T, Imai H, Yanagitani N, Sunaga N, Hisada T, and Ishizuka T, et al. (2009) Correlation of angiogenesis with 18FFMT and 18F-FDG uptake in non-small cell lung cancer. Cancer Sci 100:753-758.
147. Kang L, Wang RF, Yan P, Liu M, Zhang CL, Yu MM, Cui YG, and Xu XJ (2010) Noninvasive visualization of RNA delivery with 99mTc-radiolabeled smallinterference RNA in tumor xenografts. J Nucl Med 51:978-986.
148. Kawamura K, Yamasaki T, Yui J, Hatori A, Konno F, Kumata K, Irie T, Fukumura T, Suzuki K, and Kanno I, et al. (2009) In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [(11)C]gefitinib. Nucl Med Biol 36:239-246.
149. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, and Aboagye EO (2007) Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 39-deoxy-39-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34:1339-1347.
150. Kenny LM, Coombes RC, Oulie I, Contractor KB, Miller M, Spinks TJ, McParland B, Cohen PS, Hui AM, and Palmieri C, et al. (2008) Phase I trial of the positronemitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med 49:879-886.
151. Kenny LM, Vigushin DM, Al-Nahhas A, Osman S, Luthra SK, Shousha S, Coombes RC, and Aboagye EO (2005) Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res 65: 10104-10112.
152. Kim EM, Jeong MH, Kim DW, Jeong HJ, Lim ST, and Sohn MH (2011) Iodine 125-labeled mesenchymal-epithelial transition factor binding peptide-click-cRGDyk heterodimer for glioma imaging. Cancer Sci 102:1516-1521.
153. Kim EM, Joung MH, Lee CM, Jeong HJ, Lim ST, Sohn MH, and Kim DW (2010) Synthesis of Tc-99m labeled 1,2,3-triazole-4-yl c-met binding peptide as a potential c-met receptor kinase positive tumor imaging agent. Bioorg Med Chem Lett 20: 4240-4243.
154. Kim EM, Park EH, Cheong SJ, Lee CM, Kim DW, Jeong HJ, Lim ST, Sohn MH, Kim K, and Chung J (2009) Characterization, biodistribution and small-animal SPECT of I-125-labeled c-Met binding peptide in mice bearing c-Met receptor tyrosine kinase-positive tumor xenografts. Nucl Med Biol 36:371-378.
155. Kishino T, Hoshikawa H, Nishiyama Y, Yamamoto Y, and Mori N (2012) Usefulness of 39-deoxy-39-18F-fluorothymidine PET for predicting early response to chemoradiotherapy in head and neck cancer. J Nucl Med 53:1521-1527.
156. Koch CJ, Scheuermann JS, Divgi C, Judy KD, Kachur AV, Freifelder R, Reddin JS, Karp J, Stubbs JB, and Hahn SM, et al. (2010) Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma. Eur J Nucl Med Mol Imaging 37: 2048-2059.
157. Komar G, Oikonen V, Sipilä H, Seppänen M, and Minn H (2012) Noninvasive parametric blood flow imaging of head and neck tumours using [15O]H2O and PET/CT. Nucl Med Commun 33:1169-1178.
158. Koopmans KP, Neels ON, Kema IP, Elsinga PH, Links TP, de Vries EG, and Jager PL (2009) Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. Crit Rev Oncol Hematol 71:199-213.
159. Kramer-Marek G, Kiesewetter DO, and Capala J (2009) Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)Flabeled affibody molecules. J Nucl Med 50:1131-1139.
160. Kramer-Marek G, Shenoy N, Seidel J, Griffiths GL, Choyke P, and Capala J (2011) 68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET. Eur J Nucl Med Mol Imaging 38:1967-1976.
161. Krausz Y, Freedman N, Rubinstein R, Lavie E, Orevi M, Tshori S, Salmon A, Glaser B, Chisin R, and Mishani E, et al. (2011) 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with 111In-DTPA-octreotide (OctreoScan®). Mol Imaging Biol 13:583-593.
162. Krausz Y, Rubinstein R, Appelbaum L, Mishani E, Orevi M, Fraenkel M, Tshori S, Glaser B, Bocher M, and Salmon A, et al. (2012) Ga-68 DOTA-NOC uptake in the pancreas: pathological and physiological patterns. Clin Nucl Med 37:57-62.
163. Kumar U (2011) Cross-talk and modulation of signaling between somatostatin and growth factor receptors. Endocrine 40:168-180.
164. la Fougère C, Suchorska B, Bartenstein P, Kreth FW, and Tonn JC (2011) Molecular imaging of gliomas with PET: opportunities and limitations. Neuro-oncol 13: 806-819.
165. Lamberts SW, de Herder WW, and Hofland LJ (2002) Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab 13:451-457.
166. Lappano R and Maggiolini M (2011) G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 10:47-60.
167. Larson SM, Morris M, Gunther I, Beattie B, Humm JL, Akhurst TA, Finn RD, Erdi Y, Pentlow K, and Dyke J, et al. (2004) Tumor localization of 16b-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 45:366-373.
168. Larsson LG (2011) Oncogene-and tumor suppressor gene-mediated suppression of cellular senescence. Semin Cancer Biol 21:367-376.
169. Laverman P, Boerman OC, Corstens FH, and Oyen WJ (2002) Fluorinated amino acids for tumour imaging with positron emission tomography. Eur J Nucl Med Mol Imaging 29:681-690.
170. Lears KA, Ferdani R, Liang K, Zheleznyak A, Andrews R, Sherman CD, Achilefu S, Anderson CJ, and Rogers BE (2011) In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer. J Nucl Med 52:470-477.
171. Lee DC, Fenton SE, Berkowitz EA, and Hissong MA (1995) Transforming growth factor alpha: expression, regulation, and biological activities. Pharmacol Rev 47: 51-85.
172. Lee ST and Scott AM (2007) Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole. Semin Nucl Med 37:451-461.
173. Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, Yu JQ, Vallabhajosula S, Schoder H, and English P, et al. (2012) Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 119:4597-4607.
174. Leu JI, Dumont P, Hafey M, Murphy ME, and George DL (2004) Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 6: 443-450.
175. Lewis JS, Laforest R, Dehdashti F, Grigsby PW, Welch MJ, and Siegel BA (2008) An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med 49:1177-1182.
176. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, Boak BB, and Wendel DP (1999) Defective angiogenesis in mice lacking endoglin. Science 284:1534-1537.
177. Li H, Xu D, Toh BH, and Liu JP (2006) TGF-beta and cancer: is Smad3 a repressor of hTERT gene? Cell Res 16:169-173.
178. Li W, Niu G, Lang L, Guo N, Ma Y, Kiesewetter DO, Backer JM, Shen B, and Chen X (2012a) PET imaging of EGF receptors using [18F]FBEM-EGF in a head and neck squamous cell carcinoma model. Eur J Nucl Med Mol Imaging 39:300-308.
179. Li X, Link JM, Stekhova S, Yagle KJ, Smith C, Krohn KA, and Tait JF (2008) Sitespecific labeling of annexin V with F-18 for apoptosis imaging. Bioconjug Chem 19: 1684-1688.
180. Li Z, Graf NA, Herrmann K, Jünger A, Aichler M, Feuchtinger A, Baumgart A, Walch A, Peschel C, and Schwaiger M, et al. (2012b) FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy. Cancer Res 72:5014-5024.
181. Lin HH (2012) Adhesion family of G protein-coupled receptors and cancer. Chang Gung Med J 35:15-27.
182. Lin LL, Silvoniemi A, Stubbs JB, Rengan R, Suilamo S, Solin O, Divgi C, Eskola O, Sorger JM, and Stabin MG, et al. (2012) Radiation dosimetry and biodistribution of the hypoxia tracer (18)F-EF5 in oncologic patients. Cancer Biother Radiopharm 27: 412-419.
183. Lingner J, Cooper JP, and Cech TR (1995) Telomerase and DNA end replication: no longer a lagging strand problem? Science 269:1533-1534.
184. Liu A, Dence CS, Welch MJ, and Katzenellenbogen JA (1992) Fluorine-18-labeled androgens: radiochemical synthesis and tissue distribution studies on six fluorinesubstituted androgens, potential imaging agents for prostatic cancer. J Nucl Med 33:724-734.
185. Liu M, Wang RF, Zhang CL, Yan P, Yu MM, Di LJ, Liu HJ, and Guo FQ (2007) Noninvasive imaging of human telomerase reverse transcriptase (hTERT) messenger RNA with 99mTc-radiolabeled antisense probes in malignant tumors. J Nucl Med 48:2028-2036.
186. Liu N, Li M, Li X, Meng X, Yang G, Zhao S, Yang Y, Ma L, Fu Z, and Yu J (2009) PETbased biodistribution and radiation dosimetry of epidermal growth factor receptorselective tracer 11C-PD153035 in humans. J Nucl Med 50:303-308.
187. Liu S (2006) Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. Mol Pharm 3:472-487.
188. Lopci E, Piccardo A, Nanni C, Altrinetti V, Garaventa A, Pession A, Cistaro A, Chiti A, Villavecchia G, and Fanti S (2012) 18F-DOPA PET/CT in neuroblastoma: comparison of conventional imaging with CT/MR. Clin Nucl Med 37:e73-e78.
189. Ma YY and Tao HQ (2012) Role of urokinase plasminogen activator receptor in gastric cancer: a potential therapeutic target. Cancer Biother Radiopharm 27: 285-290.
190. Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, Eshraghi M, Manda KD, Wiechec E, and Los M (2007) Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat 10:13-29.
191. Mankoff DA, Shields AF, Graham MM, Link JM, Eary JF, and Krohn KA (1998) Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: compartmental model and mathematical analysis. J Nucl Med 39:1043-1055.
192. Martínez-Rumayor A, Arrieta O, Guevara P, Escobar E, Rembao D, Salina C, and Sotelo J (2004) Coexpression of hepatocyte growth factor/scatter factor (HGF/SF) and its receptor cMET predict recurrence of meningiomas. Cancer Lett 213: 117-124.
193. McCall KC, Humm JL, Bartlett R, Reese M, and Carlin S (2012) Copper-64-diacetylbis (N(4)-methylthiosemicarbazone) pharmacokinetics in FaDu xenograft tumors and correlation with microscopic markers of hypoxia. Int J Radiat Oncol Biol Phys 84:e393-e399.
194. McCubrey JA, Milella M, Tafuri A, Martelli AM, Lunghi P, Bonati A, Cervello M, Lee JT, and Steelman LS (2008a) Targeting the Raf/MEK/ERK pathway with smallmolecule inhibitors. Curr Opin Investig Drugs 9:614-630.
195. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, and Tafuri A, et al. (2008b) Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 22:708-722.
196. McKeague M and Derosa MC (2012) Challenges and opportunities for small molecule aptamer development. J Nucleic Acids 2012:748913.
197. Mease RC, Dusich CL, Foss CA, Ravert HT, Dannals RF, Seidel J, Prideaux A, Fox JJ, Sgouros G, and Kozikowski AP, et al. (2008) N-[N-[(S)-1,3-Dicarboxypropyl] carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res 14:3036-3043.
198. Memon AA, Jakobsen S, Dagnaes-Hansen F, Sorensen BS, Keiding S, and Nexo E (2009) Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Cancer Res 69:873-878.
199. Memon AA, Weber B, Winterdahl M, Jakobsen S, Meldgaard P, Madsen HH, Keiding S, Nexo E, and Sorensen BS (2011) PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer. Br J Cancer 105: 1850-1855.
200. Mendelsohn J and Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21:2787-2799.
201. Meng X, Loo BW Jr, Ma L, Murphy JD, Sun X, and Yu J (2011) Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study. J Nucl Med 52:1573-1579.
202. Meric-Bernstam F and Hung MC (2006) Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res 12: 6326-6330.
203. Miao Z, Ren G, Liu H, Jiang L, and Cheng Z (2010) Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein. Bioconjug Chem 21:947-954.
204. Miao Z, Ren G, Liu H, Qi S, Wu S, and Cheng Z (2012) PET of EGFR expression with an 18F-labeled affibody molecule. J Nucl Med 53:1110-1118.
205. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, and Moll UM (2003) p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11:577-590.
206. Milenic DE, Wong KJ, Baidoo KE, Nayak TK, Regino CA, Garmestani K, and Brechbiel MW (2010) Targeting HER2: a report on the in vitro and in vivo preclinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials. MAbs 2:550-564.
207. Miles D, Harbeck N, Escudier B, Hurwitz H, Saltz L, Van Cutsem E, Cassidy J, Mueller B, and Sirzén F (2011) Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 29: 83-88.
208. Mishani E and Abourbeh G (2007) Cancer molecular imaging: radionuclide-based biomarkers of the epidermal growth factor receptor (EGFR). Curr Top Med Chem 7: 1755-1772.
209. Mishani E, Abourbeh G, Eiblmaier M, and Anderson CJ (2008) Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. Curr Pharm Des 14:2983-2998.
210. Mittra ES, Goris ML, Iagaru AH, Kardan A, Burton L, Berganos R, Chang E, Liu S, Shen B, and Chin FT, et al. (2011) Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging a(v)b(3) integrin levels. Radiology 260:182-191.
211. Montgomery AJ, Lingford-Hughes AR, Egerton A, Nutt DJ, and Grasby PM (2007) The effect of nicotine on striatal dopamine release in man: A [11C]raclopride PET study. Synapse 61:637-645.
212. Morris MJ, Divgi CR, Pandit-Taskar N, Batraki M, Warren N, Nacca A, Smith-Jones P, Schwartz L, Kelly WK, and Slovin S, et al. (2005) Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res 11:7454-7461.
213. Morris MJ, Pandit-Taskar N, Divgi CR, Bender S, O'Donoghue JA, Nacca A, Smith-Jones P, Schwartz L, Slovin S, and Finn R, et al. (2007) Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin Cancer Res 13: 2707-2713.
214. Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, Alsner J, Sørensen BS, Toustrup K, and Jakobsen S, et al. (2012) FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol 105: 14-20.
215. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, and Wagner SN, et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50-56.
216. Nagengast WB, de Korte MA, Oude Munnink TH, Timmer-Bosscha H, den Dunnen WF, Hollema H, de Jong JR, Jensen MR, Quadt C, and Garcia-Echeverria C, et al. (2010) 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med 51:761-767.
217. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, and Cech TR (1997) Telomerase catalytic subunit homologs from fission yeast and human. Science 277:955-959.
218. Nanda PK, Pandey U, Bottenus BN, Rold TL, Sieckman GL, Szczodroski AF, Hoffman TJ, and Smith CJ (2012) Bombesin analogues for gastrin-releasing peptide receptor imaging. Nucl Med Biol 39:461-471.
219. Nayak TK, Garmestani K, Baidoo KE, Milenic DE, and Brechbiel MW (2011) PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A0-DTPAbevacizumab. Int J Cancer 128:920-926.
220. Nayak TK, Garmestani K, Milenic DE, and Brechbiel MW (2012) PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab. J Nucl Med 53:113-120.
221. Nguyen QD, Smith G, Glaser M, Perumal M, Arstad E, and Aboagye EO (2009) Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide. Proc Natl Acad Sci USA 106:16375-16380.
222. Niemeyer MG, Kuijper AF, Gerhards LJ, D'Haene EG, and van der Wall EE (1993) Nitrogen-13 ammonia perfusion imaging: relation to metabolic imaging. Am Heart J 125:848-854.
223. Nimmagadda S, Pullambhatla M, Stone K, Green G, Bhujwalla ZM, and Pomper MG (2010) Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography. Cancer Res 70: 3935-3944.
224. Nishimura K, Hida S, Nishio Y, Ohishi K, Okada Y, Okada K, Yoshida O, Nishimura K, and Nishibuchi S (1988) The validity of magnetic resonance imaging (MRI) in the staging of bladder cancer: comparison with computed tomography (CT) and transurethral ultrasonography (US). Jpn J Clin Oncol 18:217-226.
225. Niu G, Cai W, and Chen X (2008) Molecular imaging of human epidermal growth factor receptor 2 (HER-2) expression. Front Biosci 13:790-805.
226. Niu G, Li Z, Xie J, Le QT, and Chen X (2009) PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med 50:1116-1123.
227. Niu G, Murad YM, Gao H, Hu S, Guo N, Jacobson O, Nguyen TD, Zhang J, and Chen X (2012) Molecular targeting of CEACAM6 using antibody probes of different sizes. J Control Release 161:18-24.
228. Niu G, Zhu L, Ho DN, Zhang F, Gao H, Quan Q, Hida N, Ozawa T, Liu G, and Chen X (2013) Longitudinal bioluminescence imaging of the dynamics of Doxorubicin induced apoptosis. Theranostics 3:190-200.
229. Oberg K (2012) Molecular imaging radiotherapy: theranostics for personalized patient management of neuroendocrine tumors (NETs). Theranostics 2:448-458.
230. Oliveira S, Schiffelers RM, van der Veeken J, van der Meel R, Vongpromek R, van Bergen En Henegouwen PM, Storm G, and Roovers RC (2010) Downregulation of EGFR by a novel multivalent nanobody-liposome platform. J Control Release 145: 165-175.
231. Olsson AK, Dimberg A, Kreuger J, and Claesson-Welsh L (2006) VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 7:359-371.
232. Orevi M, Klein M, Mishani E, Chisin R, Freedman N, and Gofrit ON (2012) 11CAcetate PET/CT in bladder urothelial carcinoma: intraindividual comparison with 11C-choline. Clin Nucl Med 37:e67-e72.
233. Otrock ZK, Hatoum HA, Awada AH, Ishak RS, and Shamseddine AI (2009) Hypoxiainducible factor in cancer angiogenesis: structure, regulation and clinical perspectives. Crit Rev Oncol Hematol 70:93-102.
234. Oude Munnink TH, Arjaans ME, Timmer-Bosscha H, Schröder CP, Hesselink JW, Vedelaar SR, Walenkamp AM, Reiss M, Gregory RC, and Lub-de Hooge MN, et al. (2011) PET with the 89Zr-labeled transforming growth factor-b antibody fresolimumab in tumor models. J Nucl Med 52:2001-2008.
235. (89)Zrtrastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVPAUY922 in a human tumour xenograft. Eur J Cancer 46:678-684.
236. Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, Dumont J, and Vassart G (1993) Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365:649-651.
237. Paudyal B, Paudyal P, Oriuchi N, Hanaoka H, Tominaga H, and Endo K (2011) Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts. Cancer Sci 102:117-121.
238. Paudyal P, Paudyal B, Hanaoka H, Oriuchi N, Iida Y, Yoshioka H, Tominaga H, Watanabe S, Watanabe S, and Ishioka NS, et al. (2010) Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET. Cancer Sci 101:1045-1050.
239. Peng L, Liu R, Marik J, Wang X, Takada Y, and Lam KS (2006) Combinatorial chemistry identifies high-affinity peptidomimetics against a4b1 integrin for in vivo tumor imaging. Nat Chem Biol 2:381-389.
240. Pérez-Gómez E, Del Castillo G, Juan Francisco S, López-Novoa JM, Bernabéu C, and Quintanilla M (2010) The role of the TGF-b coreceptor endoglin in cancer. ScientificWorldJournal 10:2367-2384.
241. Perk LR, Stigter-van Walsum M, Visser GW, Kloet RW, Vosjan MJ, Leemans CR, Giaccone G, Albano R, Comoglio PM, and van Dongen GA (2008) Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging 35:1857-1867.
242. Persson M, Madsen J, Østergaard S, Jensen MM, Jørgensen JT, Juhl K, Lehmann C, Ploug M, and Kjaer A (2012a) Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion. J Nucl Med 53:138-145.
243. Persson M, Madsen J, Østergaard S, Ploug M, and Kjaer A (2012b) 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA-and NODAGA-conjugated peptide for PET imaging of invasive cancers. Nucl Med Biol 39:560-569.
244. Pfeifer A, Knigge U, Mortensen J, Oturai P, Berthelsen AK, Loft A, Binderup T, Rasmussen P, Elema D, and Klausen TL, et al. (2012) Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study. J NuclMed 53:1207-1215.
245. Picchio M and Castellucci P (2012) Clinical indications of C-choline PET/CT in prostate cancer patients with biochemical relapse. Theranostics 2:313-317.
246. Polager S and Ginsberg D (2008) E2F-at the crossroads of life and death. Trends Cell Biol 18:528-535.
247. Polager S and Ginsberg D (2009) p53 and E2f: partners in life and death. Nat Rev Cancer 9:738-748.
248. Porter AC and Vaillancourt RR (1998) Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 17 (11 Reviews): 1343-1352.
249. Prenzel N, Fischer OM, Streit S, Hart S, and Ullrich A (2001) The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8:11-31.
250. Prigent SA and Lemoine NR (1992) The type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog Growth Factor Res 4:1-24.
251. Rahmim A and Zaidi H (2008) PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun 29:193-207.
252. Rajendran JG and Krohn KA (2005) Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am 43:169-187.
253. Ramos-Suzarte M, Rodríguez N, Oliva JP, Iznaga-Escobar N, Perera A, Morales A, Gonzalez N, Cordero M, Torres L, and Pimentel G, et al. (1999) 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy. J Nucl Med 40:768-775.
254. Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, and Krohn KA (1996) Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 36:417-428.
255. Reubi JC and Waser B (2003) Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 30:781-793.
256. Ritter CA and Arteaga CL (2003) The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol 30(1, Suppl 1) 3-11.
257. Rizvi SN, Visser OJ, Vosjan MJ, van Lingen A, Hoekstra OS, Zijlstra JM, Huijgens PC, van Dongen GA, and Lubberink M (2012) Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET. Eur J Nucl Med Mol Imaging 39:512-520.
258. Robinson SD, Reynolds LE, Wyder L, Hicklin DJ, and Hodivala-Dilke KM (2004) Beta3-integrin regulates vascular endothelial growth factor-A-dependent permeability. Arterioscler Thromb Vasc Biol 24:2108-2114.
259. 11C]-choline PET/CT in imaging locally advanced prostate cancer. Nucl Med Rev Cent East Eur 14: 118-119.
260. Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, Spencer S, Adams BJ, Alvarez D, and Seon BK, et al. (2012) A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res 18:4820-4829.
261. Rundhaug JE (2003) Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart et al., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res., 9: 00-00, 2003. Clin Cancer Res 9:551-554.
262. Ryu JS, Kim JS, Moon DH, Kim SM, Shin MJ, Chang JS, Park SK, Han DJ, and Lee HK (2002) Bone SPECT is more sensitive than MRI in the detection of early osteonecrosis of the femoral head after renal transplantation. J Nucl Med 43: 1006-1011.
263. Sakurai T and Kudo M (2011) Signaling pathways governing tumor angiogenesis. Oncology 81 (Suppl 1):24-29.
264. Saleem A, Charnley N, and Price P (2006) Clinical molecular imaging with positron emission tomography. Eur J Cancer 42:1720-1727.
265. Santos AF, Huang H, and Tindall DJ (2004) The androgen receptor: a potential target for therapy of prostate cancer. Steroids 69:79-85.
266. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, and Alumkal J, et al.; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375: 1437-1446.
267. Schillaci O and Simonetti G (2004) Fusion imaging in nuclear medicine-applications of dual-modality systems in oncology. Cancer Biother Radiopharm 19:1-10.
268. Schnell O, Krebs B, Carlsen J, Miederer I, Goetz C, Goldbrunner RH, Wester HJ, Haubner R, Pöpperl G, and Holtmannspötter M, et al. (2009) Imaging of integrin a(v)b(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro-oncol 11:861-870.
269. Schuetz M, Schmid MP, Pötter R, Kommata S, Georg D, Lukic D, Dudczak R, Kletter K, Dimopoulos J, and Karanikas G, et al. (2010) Evaluating repetitive 18Ffluoroazomycin-arabinoside (18FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer. Acta Oncol 49:941-947.
270. Schuster DM, Votaw JR, Nieh PT, Yu W, Nye JA, Master V, Bowman FD, Issa MM, and Goodman MM (2007) Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 48:56-63.
271. Schuurbiers OC, Kaanders JH, van der Heijden HF, Dekhuijzen RP, Oyen WJ, and Bussink J (2009) The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. J Thorac Oncol 4:761-767.
272. Schwarzenböck S, Souvatzoglou M, and Krause BJ (2012) Choline PET and PET/CT in primary diagnosis and staging of prostate cancer. Theranostics 2:318-330.
273. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, and Shapiro CL, et al. (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642-1649.
274. Semenza GL (2012) Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 33:207-214.
275. Shang B, Cao Z, and Zhou Q (2012) Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives. Fr Medecine 6:67-78.
276. Shay JW and Bacchetti S (1997) A survey of telomerase activity in human cancer. Eur J Cancer 33:787-791.
277. Shenker A, Laue L, Kosugi S, Merendino JJ Jr, Minegishi T, and Cutler GB Jr (1993) A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 365:652-654.
278. Shi J, Kim YS, Zhai S, Liu Z, Chen X, and Liu S (2009) Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG (4) linkers. Bioconjug Chem 20:750-759.
279. Shi Y (2006) Mechanical aspects of apoptosome assembly. Curr Opin Cell Biol 18: 677-684.
280. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O, and Mangner TJ (1998a) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4:1334-1336.
281. Shields AF, Mankoff DA, Link JM, Graham MM, Eary JF, Kozawa SM, Zheng M, Lewellen B, Lewellen TK, and Grierson JR, et al. (1998b) Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med 39:1757-1762.
282. Shiue CY and Welch MJ (2004) Update on PET radiopharmaceuticals: life beyond fluorodeoxyglucose. Radiol Clin North Am 42:1033-1053, viii.
283. Shokeen M, Zheleznyak A, Wilson JM, Jiang M, Liu R, Ferdani R, Lam KS, Schwarz JK, and Anderson CJ (2012) Molecular imaging of very late antigen-4 (a4b1 integrin) in the premetastatic niche. J Nucl Med 53:779-786.
284. Siegel PM and Massagué J (2003) Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3:807-821.
285. Smith TA (2010) Towards detecting the HER-2 receptor and metabolic changes induced by HER-2-targeted therapies using medical imaging. Br J Radiol 83: 638-644.
286. (18)F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment. Eur J Cancer 48:416-424.
287. Spanaki MV, Spencer SS, Corsi M, MacMullan J, Seibyl J, and Zubal IG (1999) Sensitivity and specificity of quantitative difference SPECT analysis in seizure localization. J Nucl Med 40:730-736.
288. Spano D, Heck C, De Antonellis P, Christofori G, and Zollo M (2012) Molecular networks that regulate cancer metastasis. Semin Cancer Biol 22:234-249.
289. Spano D and ZolloM (2012) Tumor microenvironment: a main actor in the metastasis process. Clin Exp Metastasis 29:381-395.
290. Spiegelberg BD and Hamm HE (2007) Roles of G-protein-coupled receptor signaling in cancer biology and gene transcription. Curr Opin Genet Dev 17:40-44.
291. Sprague JE, Li WP, Liang K, Achilefu S, and Anderson CJ (2006) In vitro and in vivo investigation of matrix metalloproteinase expression in metastatic tumor models. Nucl Med Biol 33:227-237.
292. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, and Krek W (2003) Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425:307-311.
293. Stanelle J and Pützer BM (2006) E2F1-induced apoptosis: turning killers into therapeutics. Trends Mol Med 12:177-185.
294. Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, and Tafuri A, et al. (2008) Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 22: 686-707.
295. Su H, Seimbille Y, Ferl GZ, Bodenstein C, Fueger B, Kim KJ, Hsu YT, Dubinett SM, Phelps ME, and Czernin J, et al. (2008) Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging 35:1089-1099.
296. Sun H, Mangner TJ, Collins JM, Muzik O, Douglas K, and Shields AF (2005a) Imaging DNA synthesis in vivo with 18F-FMAU and PET. J Nucl Med 46:292-296.
297. Sun H, Sloan A, Mangner TJ, Vaishampayan U, Muzik O, Collins JM, Douglas K, and Shields AF (2005b) Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer. Eur J Nucl Med Mol Imaging 32: 15-22.
298. Sun X, Niu G, Chan N, Shen B, and Chen X (2011) Tumor hypoxia imaging. Mol Imaging Biol 13:399-410.
299. Surati M, Patel P, Peterson A, and Salgia R (2011) Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther 11:1655-1662.
300. Tafti BA, Shaba W, Li Y, Yevdayev E, and Berenji GR (2012) Staging and follow-up of lacrimal gland carcinomas by 18F-FDG PET/CT imaging. Clin Nucl Med 37: e249-252.
301. Takeuchi K and Ito F (2011) Receptor tyrosine kinases and targeted cancer therapeutics. Biol Pharm Bull 34:1774-1780.
302. Tan H, Chen L, Guan Y, and Lin X (2011) Comparison of MRI, F-18 FDG, and 11Ccholine PET/CT for their potentials in differentiating brain tumor recurrence from brain tumor necrosis following radiotherapy. Clin Nucl Med 36:978-981.
303. Tateishi K, Tateishi U, Sato M, Yamanaka S, Kanno H, Murata H, Inoue T, and Kawahara N (2013) Application of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1a expression in patients with glioma. AJNR Am J Neuroradiol 34:92-99.
304. te Beek ET, de Boer P, Moerland M, Schmidt ME, Hoetjes NJ, Windhorst AD, van Berckel BN, Cohen AF, van Gerven JM, and Lammertsma AA (2012) In vivo quantification of striatal dopamine D2 receptor occupancy by JNJ-37822681 using [11C]raclopride and positron emission tomography. J Psychopharmacol 26: 1128-1135.
305. Teicher BA and Fricker SP (2010) CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 16:2927-2931.
306. Ter-Pogossian MM and Herscovitch P (1985) Radioactive oxygen-15 in the study of cerebral blood flow, blood volume, and oxygen metabolism. Semin Nucl Med 15: 377-394.
307. Thorwarth D, Eschmann SM, Holzner F, Paulsen F, and Alber M (2006) Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol 80:151-156.
308. Tsai CM, Chang KT, Perng RP, Mitsudomi T, Chen MH, Kadoyama C, and Gazdar AF (1993) Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst 85:897-901.
309. Turpeenniemi-Hujanen T (2005) Gelatinases (MMP-2 and-9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 87:287-297.
310. Ujula T, Huttunen M, Luoto P, Peräkylä H, Simpura I, Wilson I, Bergman M, and Roivainen A (2010) Matrix metalloproteinase 9 targeting peptides: syntheses, 68Ga-labeling, and preliminary evaluation in a rat melanoma xenograft model. Bioconjug Chem 21:1612-1621.
311. Urban NB, Slifstein M, Thompson JL, Xu X, Girgis RR, Raheja S, Haney M, and Abi-Dargham A (2012) Dopamine release in chronic cannabis users: a [11c]raclopride positron emission tomography study. Biol Psychiatry 71:677-683.
312. Vanhaesebroeck B and Alessi DR (2000) The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 346:561-576.
313. van Waarde A, Rybczynska AA, Ramakrishnan N, Ishiwata K, Elsinga PH, and Dierckx RA (2010) Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands. Curr Pharm Des 16:3519-3537.
314. Vanzetta I (2006) Hemodynamic responses in cortex investigated with optical imaging methods. Implications for functional brain mapping. J Physiol Paris 100: 201-211.
315. Vavere AL, Kridel SJ, Wheeler FB, and Lewis JS (2008) 1-11C-Acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J Nucl Med 49:327-334.
316. Velikyan I (2012) Molecular imaging and radiotherapy: theranostics for personalized patient management. Theranostics 2:424-426.
317. Vilner BJ, John CS, and Bowen WD (1995) Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 55: 408-413.
318. Vivanco I and Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489-501.
319. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, and Burchmore M, et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726.
320. Vosjan MJ, Vercammen J, Kolkman JA, Stigter-van Walsum M, Revets H, and van Dongen GA (2012) Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy. Mol Cancer Ther 11:1017-1025.
321. Wald O, Shapira OM, and Izhar U (2013) CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential. Theranostics 3:26-33.
322. Wan W, Guo N, Pan D, Yu C, Weng Y, Luo S, Ding H, Xu Y, Wang L, and Lang L, et al. (2013) First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J Nucl Med 54:691-698.
323. Wang C and Youle RJ (2009) The role of mitochondria in apoptosis. Annu Rev Genet 43:95-118.
324. Wang H, Cai W, Chen K, Li ZB, Kashefi A, He L, and Chen X (2007a) A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur J Nucl Med Mol Imaging 34:2001-2010.
325. Wang H, Gao H, Guo N, Niu G, Ma Y, Kiesewetter DO, and Chen X (2012) Sitespecific labeling of scVEGF with fluorine-18 for positron emission tomography imaging. Theranostics 2:607-617.
326. Wang H, Yu JM, Yang GR, Song XR, Sun XR, Zhao SQ, Wang XW, and Zhao W (2007b) Further characterization of the epidermal growth factor receptor ligand 11C-PD153035. Chin Med J (Engl) 120:960-964.
327. Wang J and Maurer L (2005) Positron emission tomography: applications in drug discovery and drug development. Curr Top Med Chem 5:1053-1075.
328. Wang J, Sui M, and Fan W (2010) Nanoparticles for tumor targeted therapies and their pharmacokinetics. Curr Drug Metab 11:129-141.
329. Weber WA, Wester HJ, Grosu AL, Herz M, Dzewas B, Feldmann HJ, Molls M, Stöcklin G, and Schwaiger M (2000) O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 27:542-549.
330. Weiss ID and Jacobson O (2013) Molecular imaging of chemokine receptor CXCR4. Theranostics 3:76-84.
331. Weiss ID, Jacobson O, Kiesewetter DO, Jacobus JP, Szajek LP, Chen X, and Farber JM (2012) Positron emission tomography imaging of tumors expressing the human chemokine receptor CXCR4 in mice with the use of 64Cu-AMD3100. Mol Imaging Biol 14:106-114.
332. Wirth T, Kühnel F, and Kubicka S (2005) Telomerase-dependent gene therapy. Curr Mol Med 5:243-251.
333. Wu FC (1992) Testicular steroidogenesis and androgen use and abuse. Baillieres Clin Endocrinol Metab 6:373-403.
334. Xie X, Li L, Xiao X, Guo J, Kong Y, Wu M, Liu W, Gao G, Hsu JL, and Wei W, et al. (2012) Targeted expression of BikDD eliminates breast cancer with virtually no toxicity in noninvasive imaging models. Mol Cancer Ther 11:1915-1924.
335. Yang M, Gao H, Sun X, Yan Y, Quan Q, Zhang W, Mohamedali KA, Rosenblum MG, Niu G, and Chen X (2011a) Multiplexed PET probes for imaging breast cancer early response to VEGF121/rGel treatment. Mol Pharm 8:621-628.
336. Yang M, Gao H, Zhou Y, Ma Y, Quan Q, Lang L, Chen K, Niu G, Yan Y, and Chen X (2011b) 18F-labeled GRPR agonists and antagonists: A comparative study in prostate cancer imaging. Theranostics 1:220-229.
337. Yang X, Hong H, Grailer JJ, Rowland IJ, Javadi A, Hurley SA, Xiao Y, Yang Y, Zhang Y, and Nickles RJ, et al. (2011c) cRGD-functionalized, DOX-conjugated, and 64Culabeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials 32:4151-4160.
338. Yarden Y and Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137.
339. Yeh HH, Ogawa K, Balatoni J, Mukhapadhyay U, Pal A, Gonzalez-Lepera C, Shavrin A, Soghomonyan S, Flores L 2nd, and Young D, et al. (2011) Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT. Proc Natl Acad Sci USA 108:1603-1608.
340. Yhee JY, Kim SA, Koo H, Son S, Ryu JH, Youn IC, Choi K, Kwon IC, and Kim K (2012) Optical imaging of cancer-related proteases using near-infrared fluorescence matrix metalloproteinase-sensitive and cathepsin B-sensitive probes. Theranostics 2:179-189.
341. Yin D, He Y, Perera MA, Hong SS, Marhefka C, Stourman N, Kirkovsky L, Miller DD, and Dalton JT (2003) Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol Pharmacol 63:211-223.
342. Yoshimoto M, Waki A, Yonekura Y, Sadato N, Murata T, Omata N, Takahashi N, Welch MJ, and Fujibayashi Y (2001) Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol 28:117-122.
343. Yu EY, Muzi M, Hackenbracht JA, Rezvani BB, Link JM, Montgomery RB, Higano CS, Eary JF, and Mankoff DA (2011) C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy. Clin Nucl Med 36:192-198.
344. Yu ST, Yang YB, Liang GP, Li C, Chen L, Shi CM, Tang XD, Li CZ, Li L, and Wang GZ, et al. (2010) An optimized telomerase-specific lentivirus for optical imaging of tumors. Cancer Res 70:2585-2594.
345. Yu XF and Han ZC (2006) Matrix metalloproteinases in bone marrow: roles of gelatinases in physiological hematopoiesis and hematopoietic malignancies. Histol Histopathol 21:519-531.
346. Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, and Dewhirst MW (2006) Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 47:989-998.
347. Yun M, Bang SH, Kim JW, Park JY, Kim KS, and Lee JD (2009) The importance of acetyl coenzyme A synthetase for 11C-acetate uptake and cell survival in hepatocellular carcinoma. J Nucl Med 50:1222-1228.
348. Zhang L, Virani S, Zhang Y, Bhojani MS, Burgess TL, Coxon A, Galban CJ, Ross BD, and Rehemtulla A (2011a) Molecular imaging of c-Met tyrosine kinase activity. Anal Biochem 412:1-8.
349. 11c]Iressa): radiosynthesis, in vitro uptake, and in vivo imaging of intact murine fibrosarcoma. Mol Imaging Biol 12:181-191.
350. Zhang W, Ling D, Tan J, Zhang J, and Li L (2013a) Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance. Oncol Rep 29:637-645.
351. Zhang X, Paule MG, Newport GD, Zou X, Sadovova N, Berridge MS, Apana SM, Hanig JP, Slikker W Jr, and Wang C (2009) A minimally invasive, translational biomarker of ketamine-induced neuronal death in rats: microPET Imaging using 18F-annexin V. Toxicol Sci 111:355-361.
352. Zhang X, Xiong Z, Wu Y, Cai W, Tseng JR, Gambhir SS, and Chen X (2006) Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med 47:113-121.
353. Zhang Y, Hong H, and Cai W (2011b) PET tracers based on Zirconium-89. Curr Radiopharm 4:131-139.
354. Zhang Y, Hong H, Engle JW, Bean J, Yang Y, Leigh BR, Barnhart TE, and Cai W (2011c) Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA. PLoS ONE 6: e28005.
355. Zhang Y, Hong H, Orbay H, Valdovinos HF, Nayak TR, Theuer CP, Barnhart TE, and Cai W (2013b) PET imaging of CD105/endoglin expression with a 61/64Cu-labeled Fab antibody fragment. Eur J Nucl Med Mol Imaging 40:759-767.
356. Zhang Y, Hong H, Severin GW, Engle JW, Yang Y, Goel S, Nathanson AJ, Liu G, Nickles RJ, and Leigh BR, et al. (2012) ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with (89)Zr and IRDye 800CW. Am J Transl Res 4:333-346.
357. Zhao J, Lu Y, and Shen HM (2012) Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells. Cancer Lett 314:8-23.
358. Zhao P, Grabinski T, Gao C, Skinner RS, Giambernardi T, Su Y, Hudson E, Resau J, Gross M, and Vande Woude GF, et al. (2007) Identification of a met-binding peptide from a phage display library. Clin Cancer Res 13:6049-6055.
359. Zheng QH, Fei X, DeGrado TR, Wang JQ, Stone KL, Martinez TD, Gay DJ, Baity WL, Mock BH, and Glick-Wilson BE, et al. (2003) Synthesis, biodistribution and micro-PET imaging of a potential cancer biomarker carbon-11 labeled MMP inhibitor (2R)-2-[4-(6-fluorohex-1-ynyl)phenyl]sulfonylamino]-3-methylbutyric acid [11C] methyl ester. Nucl Med Biol 30:753-760.
360. Zheng QH, Fei X, Liu X, Wang JQ, Stone KL, Martinez TD, Gay DJ, Baity WL, Miller KD, and Sledge GW, et al. (2004) Comparative studies of potential cancer biomarkers carbon-11 labeled MMP inhibitors (S)-2-(49-[11C]methoxybiphenyl-4-sulfonylamino)-3-methylbutyric acid and N-hydroxy-(R)-2-[(49-[11C]methoxyphenyl) sulfonyl]benzylamino]-3-methylbutanamide. Nucl Med Biol 31:77-85.
361. Zhu L, Zhang F, Ma Y, Liu G, Kim K, Fang X, Lee S, and Chen X (2011) In vivo optical imaging of membrane-type matrix metalloproteinase (MT-MMP) activity. Mol Pharm 8:2331-2338.
362. Zimny M, Gagel B, DiMartino E, Hamacher K, Coenen HH, Westhofen M, Eble M, Buell U, and Reinartz P (2006) FDG-a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging 33:1426-1431.